Zavrski I - Search Results

1

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.

Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O. Zavrski I, et al. Biochem Biophys Res Commun. 2005 Jul 22;333(1):200-5. doi: 10.1016/j.bbrc.2005.05.098. Biochem Biophys Res Commun. 2005. PMID: 15936724

2

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. Sezer O, et al. Among authors: zavrski i. Blood. 2003 Mar 15;101(6):2094-8. doi: 10.1182/blood-2002-09-2684. Epub 2002 Nov 7. Blood. 2003. PMID: 12424190 Free article. Review.

3

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O. Heider U, et al. Among authors: zavrski i. Clin Cancer Res. 2003 Apr;9(4):1436-40. Clin Cancer Res. 2003. PMID: 12684416

4

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O. Zavrski I, et al. J Cancer Res Clin Oncol. 2003 Jul;129(7):383-91. doi: 10.1007/s00432-003-0454-6. Epub 2003 Jul 8. J Cancer Res Clin Oncol. 2003. PMID: 12851815

5

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.

Heider U, Zavrski I, Jakob C, Bängeroth K, Fleissner C, Langelotz C, Possinger K, Hofbauer LC, Viereck V, Sezer O. Heider U, et al. Among authors: zavrski i. J Cancer Res Clin Oncol. 2004 Aug;130(8):469-74. doi: 10.1007/s00432-004-0578-3. Epub 2004 Jun 15. J Cancer Res Clin Oncol. 2004. PMID: 15205949

6

Proteasome: an emerging target for cancer therapy.

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O. Zavrski I, et al. Anticancer Drugs. 2005 Jun;16(5):475-81. doi: 10.1097/00001813-200506000-00002. Anticancer Drugs. 2005. PMID: 15846112 Review.

7

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.

Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Heider U, et al. Among authors: zavrski i. Biochem Biophys Res Commun. 2005 Dec 16;338(2):687-93. doi: 10.1016/j.bbrc.2005.09.146. Epub 2005 Oct 3. Biochem Biophys Res Commun. 2005. PMID: 16216218 Review.

8

Proteasome as an emerging therapeutic target in cancer.

Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O. Zavrski I, et al. Curr Pharm Des. 2007;13(5):471-85. doi: 10.2174/138161207780162908. Curr Pharm Des. 2007. PMID: 17348844 Review.

9

Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.

Jakob C, Zavrski I, Heider U, Bollow M, Schulz CO, Fleissner C, Eucker J, Michael R, Hamm B, Possinger K, Sezer O. Jakob C, et al. Among authors: zavrski i. Clin Cancer Res. 2003 Aug 1;9(8):3047-51. Clin Cancer Res. 2003. PMID: 12912955

10

Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.

Eucker J, Bängeroth K, Zavrski I, Krebbel H, Zang C, Heider U, Jakob C, Elstner E, Possinger K, Sezer O. Eucker J, et al. Among authors: zavrski i. Anticancer Drugs. 2004 Nov;15(10):955-60. doi: 10.1097/00001813-200411000-00004. Anticancer Drugs. 2004. PMID: 15514564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page